Daxxify Injection, Powder, Lyophilized, For Solution
NDC Package 72960-112-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Other Packages
    4. Frequently Asked Questions

Package Information

Daxxify (botulinum toxin type a) injection is dAXXIFY (daxibotulinumtoxinA-lanm) is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Revance Therapeutics, Inc., this product is identified by NDC 72960-112 and is authorized under FDA application BLA761127.

Identification & Billing

NDC Package Code
72960-112-01
Package Description
1 VIAL, SINGLE-USE in 1 CARTON / 1.2 mL in 1 VIAL, SINGLE-USE
Product Code
72960-112
11-Digit Billing Format
72960011201
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Daxxify
Non-Proprietary Name
Botulinum Toxin Type A
Substance Name
Botulinum Toxin Type A
Dosage Form
Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Administration Route
Intramuscular - Administration within a muscle.
Active Ingredient(s)
BOTULINUM TOXIN TYPE A 100 U/1.2mL
Pharmacologic Class
Usage Information
DAXXIFY (daxibotulinumtoxinA-lanm) is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

Regulatory & Marketing

Labeler Name
Revance Therapeutics, Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA761127
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
09-20-2022
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J0589
Source: PDAC
INJECTION, DAXIBOTULINUMTOXINA-LANM, 1 UNIT
HCPCS Dosage 1 U
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (72960-112). Click a package code to view its specific billing and regulatory data.

72960-112-02
1 VIAL, SINGLE-USE in 1 CARTON / 1.2 mL in 1 VIAL, SINGLE-USE
72960-112-05
1 VIAL, SINGLE-USE in 1 CARTON / 1.2 mL in 1 VIAL, SINGLE-USE
72960-112-06
1 VIAL, SINGLE-USE in 1 CARTON / 1.2 mL in 1 VIAL, SINGLE-USE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72960-112-01 identifies a specific commercial package of 1 vial, single-use in 1 carton / 1.2 ml in 1 vial, single-use of Daxxify, a human prescription drug labeled by Revance Therapeutics, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This injection, powder, lyophilized, for solution is formulated for intramuscular use and contains botulinum toxin type a as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Revance Therapeutics, Inc. on September 20, 2022. The current certification is valid through December 31, 2027.

How is this Revance Therapeutics, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72960011201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72960-112-01
11-Digit CMS (5-4-2)
72960-0112-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.